Hikal Ltd Q1 FY27 Earnings Analysis

- Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact. - Animal Health business is projected to scale meaningfully over several years, supported by commercialization of existing programs and new CDMO opportunities. - Pharma business volume growth is anticipated in FY '27, with quarter-on-quarter improvement expected, although no specific guidance will be given until Q1 FY '27 results. - Crop business volume growth is positive but expected to be modest; growth will mainly come from Pharma, Animal Health, and Specialty Chemicals divisions. - The company aims for a top-line business of INR 500 crores plus in Animal Health within 4-5 years. - Long-term growth target remains INR 3,500 to 4,000 crores by FY '30, though delayed by 2-3 years. - Capital investments and strategic initiatives are expected to drive growth and improve margins going forward.

- Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with plans intact despite a 2-3 year delay. (Page 15) - No specific guidance for FY '27 yet; management will provide clearer outlook after Q1 results due to current uncertainties like the global business environment and geopolitical issues. (Pages 18, 15) - EBITDA margins improved to 20.3% in Q4 FY26, with FY26 margin at 12.9%, indicating operational improvement. (Page 5) - Growth drivers include CDMO, Pharma, Animal Health, and Specialty Chemicals divisions; Crop business will show moderate growth. (Page 15) - Investments in manufacturing and compliance expected to support medium to long-term revenue and margin growth, targeting return on capital employed (ROCE) of 18-20%. (Pages 13, 15) - FDA regulatory issues expected to resolve by end of FY '27, enabling normalization and revenue ramp-up. (Pages 13, 14) - Management is confident of year-on-year growth, aiming to build INR 500 crore+ business in 4-5 years within Animal Health division. (Page 19)

- Significant investment of about INR900 crores over the last 4 years, with INR600 crores in growth capex and INR300 crores in infrastructure and regulatory/maintenance capex. - INR300 crores growth capex invested in multipurpose assets being retooled for Pharma and Animal Health business. - New high-potency laboratory and expanded R&D center in Pune operational to enhance complex chemistry capabilities. - New pilot plant at U.S. FDA-approved Panoli facility to support growth. - Planned HPAPI manufacturing facility in Pune targeted for FY '28. - FY '26 capital expenditure of INR149 crores for debottlenecking, regulatory upgrades, and expanding CDMO capacities. - Strategic investments made in the last 12-15 months becoming operational to support next phase of growth. - Ongoing investments to upgrade quality systems and implement CAPA for regulatory compliance. - Retooling of agrochemical multipurpose plant at Panoli into a pharmaceutical facility underway, with expected revenue generation starting next financial year.

- Hikal Limited has not explicitly mentioned any current or immediate plans for new fundraising through debt or equity in the call. - Capital expenditure (capex) of INR149 crores during FY26 was financed through a balanced mix of internal accruals and debt. - The company emphasizes a targeted capital allocation prioritizing high ROI projects aligned with long-term growth. - The debt-to-equity ratio improved from 0.59 to 0.56 as of March 31, 2026, indicating prudent debt management. - Growth initiatives and expansions are currently financed through internal accruals and existing debt facilities, ensuring fiscal agility. - No specific announcements regarding fresh equity or debt raising were indicated in the transcript.

- The order book for Hikal Limited remains intact despite recent challenges. - There was a loss of business in Q4 due to FDA-related slowdowns, but recovery is expected in the next few quarters. - CDMO segment continues to have long-term orders and engagements. - Animal Health business is progressing well with validated products moving into the commercial phase. - Encouraging inquiries and RFPs received from global customers, indicating a strong commercial pipeline. - Customers have approved and reapproved facilities post-FDA issues, showing confidence and ongoing partnerships. - Order book visibility is positive with gradual improvement in volumes and commercial traction across divisions.